Clinical Trials
20
Active:3
Completed:7
Trial Phases
4 Phases
Phase 1:8
Phase 2:10
Phase 3:1
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (20 trials with phase data)β’ Click on a phase to view related trials
Phase 2
10 (50.0%)Phase 1
8 (40.0%)Not Applicable
1 (5.0%)Phase 3
1 (5.0%)Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes
Not Applicable
Not yet recruiting
- Conditions
- Primary Biliary Cholangitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-10-14
- Last Posted Date
- 2025-10-14
- Lead Sponsor
- Zydus Therapeutics Inc.
- Target Recruit Count
- 386
- Registration Number
- NCT07216235
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
Phase 2
Recruiting
- Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Interventions
- Drug: 50 mg UsnoflastDrug: 75 mg UsnoflastDrug: Placebo
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-10-10
- Lead Sponsor
- Zydus Therapeutics Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT07023835
- Locations
- πΊπΈ
Zydus US015, La Jolla, California, United States
πΊπΈZydus US008, Orange, California, United States
πΊπΈZydus US013, San Francisco, California, United States
Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease
Phase 1
Not yet recruiting
- Conditions
- Cholestatic Liver Disease
- Interventions
- First Posted Date
- 2025-02-13
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Zydus Therapeutics Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT06825559
- Locations
- πΊπΈ
Zydus Site US001, Indianapolis, Indiana, United States
Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis
Phase 3
Recruiting
- Conditions
- Primary Biliary Cholangitis
- Interventions
- First Posted Date
- 2024-05-23
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Zydus Therapeutics Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06427395
- Locations
- πΊπΈ
Zydus US007, Birmingham, Alabama, United States
πΊπΈZydus US013, Los Angeles, California, United States
πΊπΈZydus US011, Pasadena, California, United States
Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US
Phase 2
Terminated
- Conditions
- Nonalcoholic Fatty Liver Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-01-27
- Last Posted Date
- 2025-09-02
- Lead Sponsor
- Zydus Therapeutics Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT05211284
- Locations
- πΊπΈ
Zydus US004, Birmingham, Alabama, United States
πΊπΈZydus US005, La Jolla, California, United States
πΊπΈZydus US006, San Francisco, California, United States
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found